DeepSeek Is Great News for TSMC Stock, J.P. Morgan Says
FEATURE The DeepSeek moment will benefit Taiwan Semiconductor Manufacturing's business prospects, according to J.P. Morgan. On Tuesday, analyst Gokul Hariharan reiterated his Overweight rating on TSMC stock, citing the growing excitement about Chinese start-up DeepSeek's recent artificial intelligence model releases.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
This growth stock just crashed 35%! Time to buy it for my Stocks and Shares ISA?
One growth stock stuck out like a sore thumb when I opened my Stocks and Shares ISA watchlist yesterday (23 June). That was Hims & Hers Health (NYSE: HIMS), which was down almost 35%, registering it's worst-ever day. This is a share I've been watching for a while, but haven't bought yet. Even after yesterday's crash, it's still up 86% over 12 months. Could this crash be an opportune time for me to nip in and open a position? Hims & Hers is a vertically integrated pharmacy and telehealth platform focused on personalised wellness. It offers prescription and over-the-counter treatments for hair loss, mental health, skincare, sexual health, and more. In 2024, the firm's revenue soared 69% year on year to $1.5bn. However, this isn't a jam-tomorrow growth story, because both net income and free cash flow more than quadrupled in Q1 of this year. Subscribers grew 38% to 2.4m. Driving some of this eye-catching growth has been compounded GLP-1 weight-loss drugs, which the firm began selling on its platform in 2024. In May, it announced a partnership with pharmaceutical giant Novo Nordisk to sell its blockbuster Wegovy treatment. Since that announcement, Hims & Hers stock has been rocketing. Until yesterday that is, when Novo terminated the collaboration. In a statement, the firm pulled no punches, accusing Hims of 'illegal mass compounding and deceptive marketing'. It used the words 'knock-off drugs' a number of times in relation to 'personalised' doses of semaglutide that Hims continues to sell. Semaglutide is the active ingredient in Wegovy. More seriously, Novo alleges that potentially unsafe active ingredients are being sourced from foreign suppliers in China, thereby putting patients at risk. Essentially then, there are three allegations here: The continued selling of copycat versions of Wegovy, which Novo says violates regulations. Deceptive marketing of these as 'personalised' treatments. Semaglutide sourced from unapproved Chinese suppliers. In response, Hims' CEO Andrew Dudum wrote on X: 'We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice.' Dudum said Novo's management is 'misleading the public', and that the platform will continue offering access to different weight-loss treatments, including semaglutide. What to make of all this? Well, there could obviously be regulatory compliance risk here. Lawsuits appear inevitable, and there's likely at least some brand damage. Meanwhile, Novo will keep selling Wegovy with two of Hims' rivals, namely Ro and LifeMD. So the firm could lose share in the booming weight-loss space, which isn't ideal. However, there's more to the platform than just Wegovy. It was already growing strongly before GLP-1s, and its opportunity to aggregate demand in some very large health categories appears undimmed to me. It's also expanding into Europe via a recent acquisition. Hims' disruptive direct-to-consumer platform aims to be cheaper and more personalised than the traditional healthcare model. Therefore, I think shareholders should expect further industry resistance, like Uber got from taxi firms. I'd like management to reassure investors about the supply chain accusations. Ideally, this will happen when the firm reports Q2 earnings in August, if not before. But if the stock keeps falling in the coming days, I will open a starter position. The post This growth stock just crashed 35%! Time to buy it for my Stocks and Shares ISA? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Ben McPoland has positions in Novo Nordisk and Uber Technologies. The Motley Fool UK has recommended Novo Nordisk and Uber Technologies. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business of Fashion
28 minutes ago
- Business of Fashion
Target Explores Factory-Direct Shipping Model Used by Temu
Target Corp. is testing the delivery of products directly to customers' homes from factories, said people familiar with the matter, an effort by the big-box retailer to launch a service similar to the Chinese e-commerce platforms Temu and Shein. The company is seeking to broaden its range of low-cost offerings through the initiative, said the people, who asked not to be named because the test hasn't been announced. Products would primarily include apparel, household goods and other non-food items, according to the people, who added the effort is in the early stages. A Target spokeswoman said the company is constantly testing new ways to deliver products and services. 'In all cases, we uphold the high quality, responsible sourcing and sustainability standards that Target is known for and that consumers expect from us,' she said. ADVERTISEMENT The Minneapolis-based retailer has struggled to revive sales growth in recent years and is looking for new avenues following choppy store traffic, soft demand and inventory missteps. Target shares are down 28 percent so far this year, while the S&P 500 Index has risen 3.6 percent, raising pressure on management to improve results. Most online orders from Target and other US retailers get sent to warehouses before going to consumers via truck delivery. By shipping directly from production sites, Target can offer lower prices and potentially increase market share among discounters. The X factor remains the US government's move to close the so-called de minimis exemption, which for years allowed Shein and Temu to capture market share by shipping orders of less than $800 to US customers duty free. The change has eroded performance at both companies, and could also impact direct-shipping efforts of Target and other retailers. After years of price increases across the economy, shoppers are spending less on toys, clothes and other discretionary items — Target's core categories. Tariffs are creating new challenges, as are boycotts after the company pulled back on diversity initiatives earlier this year. Target slashed its full-year sales forecast in May after missing Wall Street expectations for its last quarter. Target executives acknowledged then that they are not hitting the mark. Major holidays and limited-time design collaborations are bringing shoppers into stores, but the company isn't seeing that momentum every day, executives said. To counter this, the retailer is sharpening its focus on low prices and new products. In recent months, Target has said it's speeding up product development. Target's competition includes Temu, a unit of PDD Holdings Inc., Shein, Walmart Inc. and Inc., which started a low-cost online storefront called Haul that sells most items for under $20. By Jaewon Kang ADVERTISEMENT Learn more: Op-Ed | Target's DEI Flip-Flop Came at a Price Early data indicates Target and Walmart's store traffic has declined since their DEI exit, while Costco's has grown, signalling that we may be entering a new era of consumer boycotts.
Business Wire
35 minutes ago
- Business Wire
Rosen Law Firm Encourages Sable Offshore Corp. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sable Offshore Corp. (NYSE: SOC), including those who purchased shares pursuant to Sable Offshore Corp.'s May 2025 public offering, resulting from allegations that Sable Offshore Corp. may have issued materially misleading business information to the investing public. So What: If you purchased Sable Offshore Corp. securities, including pursuant to Sable Offshore Corp.'s May 2025 public offering, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On May 28, 2025, published an article entitled 'Sable Offshore Corp stock sinks following court injunction.' The article stated that Sable Offshore Corp.'s stock had fallen after 'the California Coastal Commission was granted a preliminary injunction against the company's pipeline repair and maintenance activities within the coastal zone in unincorporated Santa Barbara County. The court's decision, which aligns with the Coastal Act's strict regulations on coastal development, has raised concerns about potential project delays and additional costs for Sable Offshore.' On this news, the price of Sable Offshore Corp. stock fell 15.3% on May 28, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
